Recent discussions on X about Relmada Therapeutics (RLMD) have been buzzing with activity, largely driven by promising clinical trial results and notable insider buying. Posts on the platform highlight a significant uptick in the stock price, with some noting a surge of over 20% in after-hours trading following positive Phase 2 data for a bladder cancer therapy. The sentiment is further fueled by reports of the CEO acquiring a substantial number of shares, interpreted by many as a strong signal of confidence in the company’s future.
While the excitement around clinical progress and insider activity dominates the conversation, there are also mentions of the company’s financial challenges, including zero revenue and reliance on external funding. Some users on X have pointed out the narrowing of quarterly losses as a positive development, while others remain cautious about the long-term outlook. This mix of optimism and concern keeps the dialogue dynamic and engaging for investors tracking RLMD’s next moves.
Note: This discussion summary was generated from an AI condensation of post data.
Relmada Therapeutics Insider Trading Activity
Relmada Therapeutics insiders have traded $RLMD stock on the open market 11 times in the past 6 months. Of those trades, 11 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $RLMD stock by insiders over the last 6 months:
- SERGIO TRAVERSA (Chief Executive Officer) has made 6 purchases buying 615,976 shares for an estimated $352,807 and 0 sales.
- CHUCK ENCE (CA and CO) purchased 228,961 shares for an estimated $103,330
- MAGED SHENOUDA (Chief Financial Officer) has made 3 purchases buying 200,000 shares for an estimated $97,208 and 0 sales.
- PAUL EDWARD KELLY (Chief Operating Officer) purchased 200,000 shares for an estimated $86,060
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Relmada Therapeutics Hedge Fund Activity
We have seen 19 institutional investors add shares of Relmada Therapeutics stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC removed 843,998 shares (-69.9%) from their portfolio in Q2 2025, for an estimated $506,651
- DRIEHAUS CAPITAL MANAGEMENT LLC added 740,006 shares (+inf%) to their portfolio in Q2 2025, for an estimated $444,225
- ACADIAN ASSET MANAGEMENT LLC removed 608,449 shares (-49.6%) from their portfolio in Q2 2025, for an estimated $365,251
- PALO ALTO INVESTORS LP removed 495,146 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $297,236
- TWO SIGMA ADVISERS, LP removed 262,900 shares (-91.3%) from their portfolio in Q2 2025, for an estimated $157,818
- CORIENT PRIVATE WEALTH LLC added 206,667 shares (+inf%) to their portfolio in Q2 2025, for an estimated $124,062
- TANG CAPITAL MANAGEMENT LLC removed 200,825 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $54,222
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
